{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:07:42Z","timestamp":1773414462984,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"DOI":"10.7759\/cureus.105157","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:24:58Z","timestamp":1773401098000},"source":"Crossref","is-referenced-by-count":0,"title":["A Narrative Review of the Therapeutic Effectiveness of Lenvatinib in Comparison With Immunotherapy for the Treatment of Non-Viral Advanced Hepatocellular Carcinoma"],"prefix":"10.7759","author":[{"given":"Pankaj","family":"Sonone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilesh","family":"Lokeshwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Dharmadhikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Puppalwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chintan","family":"Khandhedia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amey","family":"Mane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyog","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S300182","article-title":"Hepatocellular carcinoma: an overview of the changing landscape of treatment options","volume":"8","author":"Koulouris A","year":"2021","unstructured":"Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular carcinoma: an overview of the changing landscape of treatment options. J Hepatocell Carcinoma. 2021, 8:387-401. 10.2147\/JHC.S300182","journal-title":"J Hepatocell Carcinoma"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pby005","article-title":"New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance","volume":"1","author":"Karin M","year":"2018","unstructured":"Karin M. New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. Precis Clin Med. 2018, 1:21-8. 10.1093\/pcmedi\/pby005","journal-title":"Precis Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14843","article-title":"Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination","volume":"41","author":"Vo Quang E","year":"2021","unstructured":"Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int. 2021, 41:915-27. 10.1111\/liv.14843","journal-title":"Liver Int"},{"key":"ref5","article-title":"Global hepatitis report, 2017. Accessed: June 16, 2025","author":". Accessed: June 16","year":"2017","unstructured":". Accessed. June 16, 2025: Global Hepatitis Report, 2017. World Health Organization, Geneva, Switzerland; 2017. https:\/\/www.who.int\/publications\/i\/item\/9789241565455."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.17998\/jlc.2024.03.13","article-title":"Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide","volume":"24","author":"Kim DY","year":"2024","unstructured":"Kim DY. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J Liver Cancer. 2024, 24:62-70. 10.17998\/jlc.2024.03.13","journal-title":"J Liver Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10498-w","article-title":"Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study","volume":"17","author":"Prabhakar T","year":"2023","unstructured":"Prabhakar T, Kaushal K, Prasad M, et al.. Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study. Hepatol Int. 2023, 17:745-52. 10.1007\/s12072-023-10498-w","journal-title":"Hepatol Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v5.i6.311","article-title":"Non-viral factors contributing to hepatocellular carcinoma","volume":"5","author":"Hamed MA","year":"2013","unstructured":"Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol. 2013, 5:311-22. 10.4254\/wjh.v5.i6.311","journal-title":"World J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2020.10.001","article-title":"Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification","volume":"149","author":"Chidambaranathan-Reghupaty S","year":"2021","unstructured":"Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021, 149:1-61. 10.1016\/bs.acr.2020.10.001","journal-title":"Adv Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i19.2279","article-title":"Mechanisms of hepatocellular carcinoma progression","volume":"25","author":"Ogunwobi OO","year":"2019","unstructured":"Ogunwobi OO, Harricharran T, Huaman J, et al.. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol. 2019, 25:2279-93. 10.3748\/wjg.v25.i19.2279","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.719896","article-title":"Advances of targeted therapy for hepatocellular carcinoma","volume":"11","author":"Niu M","year":"2021","unstructured":"Niu M, Yi M, Li N, Wu K, Wu K. Advances of targeted therapy for hepatocellular carcinoma. Front Oncol. 2021, 11:719896. 10.3389\/fonc.2021.719896","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v11.i8.589","article-title":"Novel molecular targets in hepatocellular carcinoma","volume":"11","author":"Chow AK","year":"2020","unstructured":"Chow AK, Yau SW, Ng L. Novel molecular targets in hepatocellular carcinoma. World J Clin Oncol. 2020, 11:589-605. 10.5306\/wjco.v11.i8.589","journal-title":"World J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.05.014","article-title":"Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives","volume":"39","author":"Zhu AX","year":"2012","unstructured":"Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol. 2012, 39:493-502. 10.1053\/j.seminoncol.2012.05.014","journal-title":"Semin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2084","article-title":"Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?","volume":"16","author":"Finn RS","year":"2010","unstructured":"Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?. Clin Cancer Res. 2010, 16:390-7. 10.1158\/1078-0432.CCR-09-2084","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.17998\/jlc.2023.07.17","article-title":"The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma","volume":"23","author":"Lee MM","year":"2023","unstructured":"Lee MM, Chan LL, Chan SL. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma. J Liver Cancer. 2023, 23:262-71. 10.17998\/jlc.2023.07.17","journal-title":"J Liver Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100330","article-title":"Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib","volume":"6","author":"Rimini M","year":"2021","unstructured":"Rimini M, Kudo M, Tada T, et al.. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open. 2021, 6:100330. 10.1016\/j.esmoop.2021.100330","journal-title":"ESMO Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo M","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al.. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018, 391:1163-73. 10.1016\/S0140-6736(18)30207-1","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.788635","article-title":"A retrospective study of lenvatinib monotherapy or combined with programmed cell death protein 1 antibody in the treatment of patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma in China","volume":"11","author":"Zhu S","year":"2021","unstructured":"Zhu S, Liu C, Dong Y, Shao J, Liu B, Shen J. A retrospective study of lenvatinib monotherapy or combined with programmed cell death protein 1 antibody in the treatment of patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma in China. Front Oncol. 2021, 11:788635. 10.3389\/fonc.2021.788635","journal-title":"Front Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1258","article-title":"NASH and hepatocellular carcinoma: immunology and immunotherapy","volume":"29","author":"Pinter M","year":"2023","unstructured":"Pinter M, Pinato DJ, Ramadori P, Heikenwalder M. NASH and hepatocellular carcinoma: immunology and immunotherapy. Clin Cancer Res. 2023, 29:513-20. 10.1158\/1078-0432.CCR-21-1258","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12663","article-title":"Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma","volume":"5","author":"Tomonari T","year":"2021","unstructured":"Tomonari T, Sato Y, Tanaka H, et al.. Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. JGH Open. 2021, 5:1275-83. 10.1002\/jgh3.12663","journal-title":"JGH Open"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2021.00586","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: current progresses and challenges","volume":"10","author":"Teng YX","year":"2022","unstructured":"Teng YX, Xie S, Guo PP, et al.. Hepatocellular carcinoma in non-alcoholic fatty liver disease: current progresses and challenges. J Clin Transl Hepatol. 2022, 10:955-64. 10.14218\/JCTH.2021.00586","journal-title":"J Clin Transl Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112608","article-title":"The real-world data in Japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study","volume":"13","author":"Tsuchiya K","year":"2021","unstructured":"Tsuchiya K, Kurosaki M, Sakamoto A, et al.. The real-world data in Japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study. Cancers (Basel). 2021, 13:2608. 10.3390\/cancers13112608","journal-title":"Cancers (Basel)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2019.014","article-title":"Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"5","author":"Raza S","year":"2019","unstructured":"Raza S, Rajak S, Anjum B, Sinha RA. Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma. Hepatoma Res. 2019, 5:42. 10.20517\/2394-5079.2019.014","journal-title":"Hepatoma Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00762","article-title":"Recent insights into the multiple pathways driving non-alcoholic steatohepatitis-derived hepatocellular carcinoma","volume":"9","author":"Takakura K","year":"2019","unstructured":"Takakura K, Oikawa T, Nakano M, Saeki C, Torisu Y, Kajihara M, Saruta M. Recent insights into the multiple pathways driving non-alcoholic steatohepatitis-derived hepatocellular carcinoma. Front Oncol. 2019, 9:762. 10.3389\/fonc.2019.00762","journal-title":"Front Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1562947","article-title":"The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2","volume":"35","author":"Anstee QM","year":"2015","unstructured":"Anstee QM, Day CP. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin Liver Dis. 2015, 35:270-90. 10.1055\/s-0035-1562947","journal-title":"Semin Liver Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee QM","year":"2019","unstructured":"Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019, 16:411-28. 10.1038\/s41575-019-0145-7","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2010.183","article-title":"NF-\u03baB and STAT3 - key players in liver inflammation and cancer","volume":"21","author":"He G","year":"2011","unstructured":"He G, Karin M. NF-\u03baB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011, 21:159-68. 10.1038\/cr.2010.183","journal-title":"Cell Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng AL","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al.. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022, 76:862-73. 10.1016\/j.jhep.2021.11.030","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister D","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, et al.. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021, 592:450-6. 10.1038\/s41586-021-03362-0","journal-title":"Nature"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96089-x","article-title":"Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study","volume":"11","author":"Hiraoka A","year":"2021","unstructured":"Hiraoka A, Kumada T, Tada T, et al.. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep. 2021, 11:16663. 10.1038\/s41598-021-96089-x","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.11.017","article-title":"Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population","volume":"180","author":"Casadei-Gardini A","year":"2023","unstructured":"Casadei-Gardini A, Rimini M, Tada T, et al.. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer. 2023, 180:9-20. 10.1016\/j.ejca.2022.11.017","journal-title":"Eur J Cancer"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.389","article-title":"Responses to immunotherapy in hepatocellular carcinoma patients with nonalcoholic steatohepatitis cirrhosis","volume":"40","author":"Chang J","year":"2022","unstructured":"Chang J, Ryan JS, Ajmera V, Ting S, Tamayo P, Burgoyne A. Responses to immunotherapy in hepatocellular carcinoma patients with nonalcoholic steatohepatitis cirrhosis. JCO. 2022, 40:389. 10.1200\/JCO.2022.40.4_suppl.389","journal-title":"JCO"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa GK","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al.. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022, 1:EVIDoa2100070. 10.1056\/EVIDoa2100070","journal-title":"NEJM Evid"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041020","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: current strategies and biomarkers predicting response and\/or resistance","volume":"11","author":"Pelizzaro F","year":"2023","unstructured":"Pelizzaro F, Farinati F, Trevisani F. Immune checkpoint inhibitors in hepatocellular carcinoma: current strategies and biomarkers predicting response and\/or resistance. Biomedicines. 2023, 11:10.3390\/biomedicines11041020","journal-title":"Biomedicines"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100886","article-title":"Immunotherapy for HCC: limitations in patients with NASH","volume":"28","author":"Agarwal PD","year":"2023","unstructured":"Agarwal PD, Lucey MR, Said A, Kratz J. Immunotherapy for HCC: limitations in patients with NASH. Ann Hepatol. 2023, 28:100886. 10.1016\/j.aohep.2022.100886","journal-title":"Ann Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-022-00348-w","article-title":"Safety and effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma in real-world clinical practice: an observational post-marketing study in Japan","volume":"10","author":"Furuse J","year":"2023","unstructured":"Furuse J, Izumi N, Motomura K, et al.. Safety and effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma in real-world clinical practice: an observational post-marketing study in Japan. Drugs Real World Outcomes. 2023, 10:195-205. 10.1007\/s40801-022-00348-w","journal-title":"Drugs Real World Outcomes"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S411806","article-title":"Application and resistance mechanisms of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"10","author":"Tao M","year":"2023","unstructured":"Tao M, Han J, Shi J, et al.. Application and resistance mechanisms of lenvatinib in patients with advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2023, 10:1069-83. 10.2147\/JHC.S411806","journal-title":"J Hepatocell Carcinoma"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.11.020","article-title":"Real-world effectiveness of lenvatinib in hepatocellular carcinoma patients with nonalcoholic steatohepatitis","volume":"21","author":"Singal AG","year":"2023","unstructured":"Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib in hepatocellular carcinoma patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2023, 21:830-1.e1. 10.1016\/j.cgh.2021.11.020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13843","article-title":"The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma","volume":"53","author":"Shimose S","year":"2023","unstructured":"Shimose S, Hiraoka A, Casadei-Gardini A, et al.. The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma. Hepatol Res. 2023, 53:104-15. 10.1111\/hepr.13843","journal-title":"Hepatol Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1159\/000525145","article-title":"Real life study of lenvatinib therapy for hepatocellular carcinoma: RELEVANT study","volume":"11","author":"Casadei-Gardini A","year":"2022","unstructured":"Casadei-Gardini A, Rimini M, Kudo M, et al.. Real life study of lenvatinib therapy for hepatocellular carcinoma: RELEVANT study. Liver Cancer. 2022, 11:527-39. 10.1159\/000525145","journal-title":"Liver Cancer"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1159\/000517494","article-title":"Lenvatinib for hepatocellular carcinoma patients with nonviral infection who were unlikely to respond to immunotherapy: a retrospective, comparative study","volume":"99","author":"Hatanaka T","year":"2021","unstructured":"Hatanaka T, Kakizaki S, Nagashima T, et al.. Lenvatinib for hepatocellular carcinoma patients with nonviral infection who were unlikely to respond to immunotherapy: a retrospective, comparative study. Oncology. 2021, 99:641-51. 10.1159\/000517494","journal-title":"Oncology"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100591","article-title":"Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis","volume":"7","author":"Rimini M","year":"2022","unstructured":"Rimini M, Rimassa L, Ueshima K, et al.. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022, 7:100591. 10.1016\/j.esmoop.2022.100591","journal-title":"ESMO Open"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111808","article-title":"Lenvatinib is highly effective in patients with hepatocellular carcinoma related to both metabolic dysfunction-associated steatohepatitis and alcoholic etiology: a propensity score analysis","volume":"17","author":"Sacco R","year":"2025","unstructured":"Sacco R, Giannini EG, Tortora R, et al.. Lenvatinib is highly effective in patients with hepatocellular carcinoma related to both metabolic dysfunction-associated steatohepatitis and alcoholic etiology: a propensity score analysis. Cancers (Basel). 2025, 17:1808. 10.3390\/cancers17111808","journal-title":"Cancers (Basel)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071747","article-title":"Atezolizumab\/bevacizumab vs. Lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study","volume":"14","author":"Kim BK","year":"2022","unstructured":"Kim BK, Cheon J, Kim H, et al.. Atezolizumab\/bevacizumab vs. Lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study. Cancers (Basel). 2022, 14:1747. 10.3390\/cancers14071747","journal-title":"Cancers (Basel)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5506","article-title":"Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma","volume":"12","author":"Su CW","year":"2023","unstructured":"Su CW, Teng W, Lin PT, et al.. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma. Cancer Med. 2023, 12:7077-89. 10.1002\/cam4.5506","journal-title":"Cancer Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.493","article-title":"Comparison of the treatment effect between lenvatinib and atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in pathologically diagnosed metabolic dysfunction-associated steatotic liver disease","volume":"42","author":"Takahashi H","year":"2024","unstructured":"Takahashi H, Koshiyama Y, Mitsumoto Y, et al.. Comparison of the treatment effect between lenvatinib and atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in pathologically diagnosed metabolic dysfunction-associated steatotic liver disease. JCO. 2024, 42:493. 10.1200\/JCO.2024.42.3_suppl.493","journal-title":"JCO"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00390-x","article-title":"Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma","volume":"3","author":"Yamauchi M","year":"2023","unstructured":"Yamauchi M, Ono A, Amioka K, et al.. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma. Commun Med (Lond). 2023, 3:152. 10.1038\/s43856-023-00390-x","journal-title":"Commun Med (Lond)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu AX","year":"2022","unstructured":"Zhu AX, Abbas AR, de Galarreta MR, et al.. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022, 28:1599-611. 10.1038\/s41591-022-01868-2","journal-title":"Nat Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study","volume":"21","author":"Lee MS","year":"2020","unstructured":"Lee MS, Ryoo BY, Hsu CH, et al.. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020, 21:808-20. 10.1016\/S1470-2045(20)30156-X","journal-title":"Lancet Oncol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848387","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study","volume":"13","author":"Cai M","year":"2022","unstructured":"Cai M, Huang W, Huang J, et al.. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Front Immunol. 2022, 13:848387. 10.3389\/fimmu.2022.848387","journal-title":"Front Immunol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng Z","year":"2023","unstructured":"Peng Z, Fan W, Zhu B, et al.. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023, 41:117-27. 10.1200\/JCO.22.00392","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00350-4","article-title":"Recent advances in systemic therapy for hepatocellular carcinoma","volume":"10","author":"Zhang H","year":"2022","unstructured":"Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res. 2022, 10:3. 10.1186\/s40364-021-00350-4","journal-title":"Biomark Res"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i7.789","article-title":"Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and beyond","volume":"25","author":"Kudo M","year":"2019","unstructured":"Kudo M. Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and beyond. World J Gastroenterol. 2019, 25:789-807. 10.3748\/wjg.v25.i7.789","journal-title":"World J Gastroenterol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5841","article-title":"Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features","volume":"12","author":"Zou X","year":"2023","unstructured":"Zou X, Xu Q, You R, Yin G. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features. Cancer Med. 2023, 12:11315-33. 10.1002\/cam4.5841","journal-title":"Cancer Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S304820","article-title":"Lenvatinib plus camrelizumab versus lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma: a short-term prognostic study","volume":"13","author":"Wei F","year":"2021","unstructured":"Wei F, Huang Q, He J, Luo L, Zeng Y. Lenvatinib plus camrelizumab versus lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma: a short-term prognostic study. Cancer Manag Res. 2021, 13:4233-40. 10.2147\/CMAR.S304820","journal-title":"Cancer Manag Res"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2072726","article-title":"Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?","volume":"31","author":"Fulgenzi CA","year":"2022","unstructured":"Fulgenzi CA, D'Alessio A, Ogunbiyi O, et al.. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. Expert Opin Investig Drugs. 2022, 31:681-91. 10.1080\/13543784.2022.2072726","journal-title":"Expert Opin Investig Drugs"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta K","year":"2020","unstructured":"Shigeta K, Datta M, Hato T, et al.. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology. 2020, 71:1247-61. 10.1002\/hep.30889","journal-title":"Hepatology"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato Y","year":"2019","unstructured":"Kato Y, Tabata K, Kimura T, et al.. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019, 14:e0212513. 10.1371\/journal.pone.0212513","journal-title":"PLoS One"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01248-0","article-title":"Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience","volume":"40","author":"Wu WC","year":"2022","unstructured":"Wu WC, Lin TY, Chen MH, et al.. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Invest New Drugs. 2022, 40:789-97. 10.1007\/s10637-022-01248-0","journal-title":"Invest New Drugs"},{"key":"ref60","article-title":"Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study","volume":"11","author":"Xue M","year":"2021","unstructured":"Xue M, Wu Y, Zhu B, Zou X, Fan W, Li J. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study. Am J Cancer Res. 2021, 11:6107-18.","journal-title":"Am J Cancer Res"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1517","article-title":"Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models","volume":"7","author":"Matsuki M","year":"2018","unstructured":"Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, Matsui J. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018, 7:2641-53. 10.1002\/cam4.1517","journal-title":"Cancer Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452099-a-narrative-review-of-the-therapeutic-effectiveness-of-lenvatinib-in-comparison-with-immunotherapy-for-the-treatment-of-non-viral-advanced-hepatocellular-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:25:00Z","timestamp":1773401100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452099-a-narrative-review-of-the-therapeutic-effectiveness-of-lenvatinib-in-comparison-with-immunotherapy-for-the-treatment-of-non-viral-advanced-hepatocellular-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":61,"URL":"https:\/\/doi.org\/10.7759\/cureus.105157","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}